Rocket Pharmaceuticals, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $188.88M, a 544.70% increase year-over-year.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2023-03-31 was $17.22M.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2022-09-30 was $29.30M, a 11.17% increase year-over-year.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2022-06-30 was $17.24M.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2024 was $182.53M, a 3.37% decline from fiscal 2023.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2023 was $188.88M, a 74.67% increase from fiscal 2022.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2022 was $108.14M, a 310.33% increase from fiscal 2021.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2021 was $26.35M, a 90.61% decline from fiscal 2020.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-12-31 | $182.53M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $188.88M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $188.88M 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $17.22M 10-Q · filed 2023-08-09 | |
| 2022-12-31 | $108.14M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $29.30M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $17.24M 10-Q · filed 2023-08-09 | |
| 2021-12-31 | $26.35M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $26.35M 10-Q · filed 2022-11-04 | |
| 2020-12-31 | $280.76M 10-K · filed 2023-02-28 | |
| 2019-12-31 | $177.76M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $86.08M 10-Q · filed 2020-11-06 | |
| 2018-12-31 | $75.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $154.02M 10-K · filed 2021-03-01 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | |
| 2018-03-31 | $78.52M 10-Q · filed 2019-11-08 | |
| 2016-12-31 | $4.00M 10-K · filed 2018-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |